| Early Clinical Experience of Finerenone in People with Chronic Kidney Disease and Type 2 Diabetes in Japan—A Multi-Cohort Study from the FOUNTAIN (FinerenOne mUltidatabase … A Sato, D Rodriguez-Molina, K Yoshikawa-Ryan, S Yamashita, S Okami, ... Journal of Clinical Medicine 13 (17), 5107, 2024 | | 2024 |
| # 2546 CKD-PC risk model for CKD progression: validation and association with outcomes in the FIDELITY population T Shafi, SD Anker, G Filippatos, B Pitt, LM Ruilope, MD Brinker, ... Nephrology Dialysis Transplantation 39 (Supplement_1), gfae069-0633-2546, 2024 | | 2024 |
| # 2022 Clinical outcomes in US patients initiating finerenone–a report from the FOUNTAIN platform NG Oberprieler, CP Kovesdy, JB Layton, B Thapa, G Curhan, AE Farjat, ... Nephrology Dialysis Transplantation 39 (Supplement_1), gfae069-1416-2022, 2024 | | 2024 |
| Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY population N Tangri, T Ferguson, SJ Leon, SD Anker, G Filippatos, B Pitt, P Rossing, ... Clinical kidney journal 17 (4), sfae052, 2024 | | 2024 |
| IDF23-0079 Cardiorenal Events in Medication-Initiator Cohorts of Patients with Chronic Kidney Disease and Type 2 Diabetes in Japan N Kashihara, H Kanegae, S Okami, NG Oberprieler, M Pladevall-Vila, ... Diabetes Research and Clinical Practice 209, 111136, 2024 | 1 | 2024 |
| Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials S Bansal, MEF Canziani, R Birne, SD Anker, GL Bakris, G Filippatos, ... BMJ open 14 (3), e076444, 2024 | 1 | 2024 |
| Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes G Filippatos, SD Anker, GL Bakris, P Rossing, LM Ruilope, AJS Coats, ... ESC Heart Failure, 2024 | | 2024 |
| Impact of finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 diabetes: a mediation analysis R Agarwal, W Tu, AE Farjat, YMK Farag, R Toto, S Kaul, R Lawatscheck, ... Annals of internal medicine 176 (12), 1606-1616, 2023 | 21 | 2023 |
| Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials JM Flack, R Agarwal, SD Anker, B Pitt, LM Ruilope, P Rossing, SG Adler, ... Kidney Medicine 5 (12), 100730, 2023 | | 2023 |
| Effect of finerenone in patients with chronic kidney disease and type 2 diabetes by baseline anaemia status: a FIDELITY analysis A Singh, SD Anker, G Filippatos, B Pitt, P Rossing, LM Ruilope, AE Farjat, ... European Heart Journal 44 (Supplement_2), ehad655. 2792, 2023 | | 2023 |
| Finerenone in chronic kidney disease and type 2 diabetes: a FIDELITY analysis of left ventricular hypertrophy L Matavelli, G Filippatos, SD Anker, GL Bakris, P Rossing, LM Ruilope, ... American Journal of Preventive Cardiology 15, 100544, 2023 | 1 | 2023 |
| Validation of a CKD progression risk prediction model in the fidelity trial population N Tangri, T Ferguson, S Leon-Mantilla, SD Anker, B Pitt, P Rossing, ... Nephrology Dialysis Transplantation 38 (1), I643-I644, 2023 | | 2023 |
| # 4486 VALIDATION OF A CKD PROGRESSION RISK PREDICTION MODEL IN THE FIDELITY TRIAL POPULATION N Tangri, T Ferguson, S Leon-Mantilla, SD Anker, B Pitt, P Rossing, ... Nephrology Dialysis Transplantation 38 (Supplement_1), gfad063c_4486, 2023 | | 2023 |
| Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score MA De Winter, HR Büller, M Carrier, AT Cohen, JB Hansen, ... European heart journal 44 (14), 1231-1244, 2023 | 28 | 2023 |
| IDF2022-1255 Efficacy and safety of finerenone by age and sex subgroups in patients with chronic kidney disease and type 2 diabetes S Bansal, S Anker, G Bakris, G Filippatos, P Rossing, L Ruilope, R Birne, ... Diabetes Research and Clinical Practice 197, 2023 | | 2023 |
| 36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE AGG Turpie, AE Farjat, S Haas, W Ageno, JI Weitz, SZ Goldhaber, S Goto, ... Thrombosis research 222, 31-39, 2023 | 12 | 2023 |
| Impact of Finerenone-Induced Albuminuria Reduction on CKD Outcomes in Type 2 Diabetes: A Causal Mediation Analysis R Agarwal, W Tu, A Farjat, YM Farag, RD Toto, S Kaul, R Lawatscheck, ... | | 2023 |
| Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease G Filippatos, SD Anker, B Pitt, DK McGuire, P Rossing, LM Ruilope, ... European Heart Journal-Cardiovascular Pharmacotherapy 9 (1), 85-93, 2023 | 10 | 2023 |
| Finerenone and Cardiorenal Outcomes by History of Cardiovascular Disease in Patients with Type 2 Diabetes: Fidelity Analyses G Filippatos, SD Anker, B Pitt, P Rossing, LM Ruilope, DK McGuire, ... American Heart Journal 254, 253-254, 2022 | | 2022 |
| MRI quantification of placebo effect in nonalcoholic steatohepatitis clinical trials MA Nedrud, M Chaudhry, MS Middleton, CA Moylan, R Lerebours, S Luo, ... Radiology 306 (3), e220743, 2022 | 4 | 2022 |
Walter AgenoUniversità degli Studi dell'Insubria在 asst-settelaghi.it 的电子邮件经过验证
